![](/wp-content/uploads/2023/07/Screenshot-2023-07-18-at-11.12.43-AM.png)
$599
Novartis Discontinues Ph2 Obesity Asset; Novartis Q2 ‘23 Earnings; Akebia to Resubmit Vadadustat NDA
Two cardiometabolic-related news items have been observed: Novartis hosted its Q2 ‘23 earnings call and disclosed it is discontinuing the development MBL949 in obesity (view press release; slides); and Akebia Therapeutics announced it has completed the End of Dispute Type A meeting with FDA and plans to resubmit the vadadustat NDA for the treatment of anemia due to CKD in adult patients on dialysis in Q3 ‘23 (view press release). Below, FENIX provides highlights and insights into the respective news items.